Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
otilonium bromide + diazepam
- Development stage
- Unknown
- Lead developer
- Malesci Istituto Farmacobiologico
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Obispax is a fixed-dose combination pharmaceutical product developed by Malesci Pharmacobiological Institute (a subsidiary of the Menarini Group). It contains otilonium bromide, a musculotropic antispasmodic, and diazepam, a benzodiazepine. The drug is primarily indicated for the treatment of irritable bowel syndrome (IBS) and other functional gastrointestinal disorders characterized by smooth muscle spasms and a significant psychosomatic or anxiety-related component. Otilonium bromide exerts its effect locally on the gastrointestinal tract by blocking L-type calcium channels and muscarinic receptors, thereby reducing hypermotility and spasms. Diazepam provides a complementary anxiolytic and muscle-relaxant effect by modulating GABA-A receptors in the central nervous system, addressing the emotional tension often associated with chronic digestive conditions.
- Brand names
- Obispax
02
Targets
GABRR (GABA-A receptor subunit rho)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)mAChR (Muscarinic acetylcholine receptors)CaV3 (Caveolin-3)TACR2 (Neurokinin-2 Receptor)TSPO (Translocator Protein (18 kDa))LTCC (Voltage-gated calcium channel (L-type))
Beyond the preview
Go deeper on otilonium bromide + diazepam.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on otilonium bromide + diazepam.